In prostate cancer, various imaging modalities are available, but evidence is limited to use in men within secondary care rather than the general population.6,7 Multiparametric, contrast-enhanced magnetic resonance imaging (MRI) is a diagnostic test with good accuracy for detection of clinically significant cancer in men referred to the hospital with an elevated PSA level.8,9,10 Recently, biparametric, noncontrast (short) MRI protocols have been developed that offer shorter scanning times with a favorable diagnostic performance.11 This evidence concerns the gene KLK3 and prostate cancer.